- Marathon Patent Group reported record revenues of $3.8M which were up 38% from prior quarter and 151% year-over-year.
- Marathon acquired three companies each with active patent portfolios as well as one additional company with revenue rights associated with two active patent portfolios.
- Marathon unveiled its Opus Analytic IP valuation software developed by IPNav for commercial usage, which opens up a new high margin reoccurring revenue stream.
- The Q2 release affirms that Marathon is indeed a Best of Breed among patent plays with currently 82 active defendants.
- All of these events reported were anticipated and the launch of the Opus software is ahead of the original schedule.
On August 14th, Marathon Patent Group (NASDAQ:MARA) released its second quarter report. As part of the release Marathon reported record revenues of $3.8M and Non-GAAP income of $0.21/share. Revenues grew by 151% year over year and 38% from Q1 revenues. The company finished the quarter with $6.5M in cash and zero debt.
Also during the quarter, Marathon acquired three companies each with active patent portfolios as well as one additional company with revenue rights associated with two active patent portfolios. All of the subject patent portfolios are in various stages of monetization. The patents cover diverse fundamental technologies in the following areas: life sciences; natural language processing and search query; automotive-related sensors; network intrusion, detection and protection; and medical device technology.
As noted in the original article, Marathon Patent Best of Breed in Patent Space, Marathon continues to not only meet expectations, but exceed them by posting large revenue increases, acquiring producing portfolios and launching new reoccurring revenue generating platforms such as Opus Analytics. Its highly competent management team, diversified portfolio of patent assets and close working relationship with IPNav, makes it the clear value play in the space and hands down the best choice for long term share appreciation while alleviating the risk of a potential adverse binary event like the one just experienced by Vringo.
Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.